Skip to main content
Clinical Trials/NCT06182098
NCT06182098
Recruiting
Not Applicable

Value of Intravenous Fluids in the Emergent Treatment of Pediatric Migraine

Dayton Children's Hospital1 site in 1 country134 target enrollmentJune 27, 2023

Overview

Phase
Not Applicable
Intervention
Ketorolac
Conditions
Migraine
Sponsor
Dayton Children's Hospital
Enrollment
134
Locations
1
Primary Endpoint
One hour change in pain
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this clinical trial is to compare intravenous (IV) fluids in pediatric patients with migraine. The main questions it aims to answer are:

  • Does a large amount of fluids (bolus) improve pain
  • Does a large amount of fluids (bolus) reduce admissions to the hospital for migraine Participants will be asked to report their pain and have vital signs checked every 30 minutes for two hours.

Researchers will compare a large amount of fluids (bolus) to a small amount (half maintenance) to see if there is a difference in pain improvement.

Detailed Description

Patients will be randomized to one of two treatment groups. The intervention group will receive a 20 mL/kg bolus of normal saline (with a maximum of 1L), given over one hour. The control group will receive normal saline at half maintenance (with a maximum of 50mL/hr) over one hour. Both groups will receive: * ketoralac (Toradol), 0.5mg/kg, with a maximum of 30mg * diphenhydramine(Benadryl), 0.5mg/kg, with a maximum of 25mg * prochlorperazine(Compazine), 0.15mg/kg, with a maximum of 10mg Pain score, heart rate, and blood pressure will be monitored every 30 minutes from the start of the medications/fluids being started, for a period of two hours. Pain will be recorded using a 100mm visual analog scale.

Registry
clinicaltrials.gov
Start Date
June 27, 2023
End Date
June 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jonathan Elliott, MD

Principal Investigator

Dayton Children's Hospital

Eligibility Criteria

Inclusion Criteria

  • At least 1 prior headache
  • Minimum pain score of 10mm
  • Headache lasting 2-72 hours
  • At least two of the following four: 1 Bifrontal/bitemporal or unilateral location, 2 Pulsating quality, 3 Moderate or severe pain intensity, 4 Aggravation by or causing avoidance of routine physical activity
  • At least one of the following: 1 Nausea and/or vomiting, 2Photophobia and phonophobia, 3 Not better accounted for by another ICHD-3 diagnosis

Exclusion Criteria

  • Shunted hydrocephalus
  • Temperature equal to or greater than 38.5C
  • Clinical suspicion of meningitis
  • Known or suspected intracranial lesion
  • Clinical evidence of significant dehydration (or signs of shock, or attending discretion)
  • Head trauma in previous 7 days
  • Pregnancy or breastfeeding
  • Initial pain score less than 10mm
  • Allergy to study medications
  • Patients previously participating in the study

Arms & Interventions

Bolus

Will receive a normal saline bolus

Intervention: Ketorolac

Bolus

Will receive a normal saline bolus

Intervention: Diphenhydramine

Bolus

Will receive a normal saline bolus

Intervention: Prochlorperazine

Bolus

Will receive a normal saline bolus

Intervention: bolus

Control

Will receive 1/2 maintenance normal saline

Intervention: 1/2 maintenance fluids

Control

Will receive 1/2 maintenance normal saline

Intervention: Ketorolac

Control

Will receive 1/2 maintenance normal saline

Intervention: Diphenhydramine

Control

Will receive 1/2 maintenance normal saline

Intervention: Prochlorperazine

Outcomes

Primary Outcomes

One hour change in pain

Time Frame: one hour

Mean change from baseline pain score, taken at one hour from beginning data collection. A 100 mm visual analog scale is used, with a higher score indicating higher pain. A greater change in pain score means more improved pain.

Secondary Outcomes

  • return visits(Through study completion, up to 48 hours after completion of study protocol.)
  • Resolution of pain(Through study completion, up to 24 hours after enrollment)
  • length of emergency stay(Through study completion, up to 24 hours after patient enrollment.)
  • Admission rate(during emergency department visit, up to 24 hours after patient enrollment)
  • Two hour change in pain(two hours)
  • 50% reduction of pain(Through study completion, up to 24 hours after enrollment. Assessed at the time of discharge from the emergency department)

Study Sites (1)

Loading locations...

Similar Trials